JP2025504795A5 - - Google Patents
Info
- Publication number
- JP2025504795A5 JP2025504795A5 JP2024541191A JP2024541191A JP2025504795A5 JP 2025504795 A5 JP2025504795 A5 JP 2025504795A5 JP 2024541191 A JP2024541191 A JP 2024541191A JP 2024541191 A JP2024541191 A JP 2024541191A JP 2025504795 A5 JP2025504795 A5 JP 2025504795A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- bispecific antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2022/071080 | 2022-01-10 | ||
| CN2022071080 | 2022-01-10 | ||
| CN202210352672 | 2022-04-01 | ||
| CN202210352672.3 | 2022-04-01 | ||
| CN202310005123.3 | 2023-01-03 | ||
| CN202310005123 | 2023-01-03 | ||
| PCT/CN2023/071314 WO2023131328A1 (zh) | 2022-01-10 | 2023-01-09 | 一种抗体及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025504795A JP2025504795A (ja) | 2025-02-19 |
| JP2025504795A5 true JP2025504795A5 (https=) | 2026-01-20 |
Family
ID=87073288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024541191A Pending JP2025504795A (ja) | 2022-01-10 | 2023-01-09 | 抗体及びその用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20250092135A1 (https=) |
| EP (1) | EP4464722A4 (https=) |
| JP (1) | JP2025504795A (https=) |
| CN (1) | CN118510810A (https=) |
| TW (1) | TW202334234A (https=) |
| WO (1) | WO2023131328A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| CN120005019A (zh) * | 2023-11-14 | 2025-05-16 | 成都优赛诺生物科技有限公司 | 一种靶向gprc5d的单域抗体、嵌合抗原受体及其应用 |
| WO2025194478A1 (en) * | 2024-03-22 | 2025-09-25 | Biofront Ltd | Antibodies binding to cd3 and gprc5d, and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004035537A2 (en) | 2002-10-16 | 2004-04-29 | Euro-Celtique S.A. | Antibodies that bind cell-associated ca 125/o772p and methods of use thereof |
| JP2016538275A (ja) * | 2013-11-04 | 2016-12-08 | グレンマーク ファーマシューティカルズ， エセ．アー． | Ｔ細胞再標的化ヘテロ二量体免疫グロブリン（ｈｅｔｅｒｏ−ｄｉｍｅｒｉｃ ｉｍｍｕｎｏｇｌｏｂｕｌｉｎ）の製造 |
| EP3177643B1 (en) | 2014-08-04 | 2019-05-08 | F.Hoffmann-La Roche Ag | Bispecific t cell activating antigen binding molecules |
| BR112017011932A8 (pt) * | 2014-12-05 | 2022-11-08 | Memorial Sloan Kettering Cancer Center | Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso |
| TWI781108B (zh) * | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | 抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途 |
| JP7066690B2 (ja) * | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| TW202504917A (zh) | 2018-06-21 | 2025-02-01 | 美商再生元醫藥公司 | 用雙特異性抗CD3xMUC16抗體及抗PD-1抗體治療癌症之方法 |
| CN114174338A (zh) * | 2019-07-31 | 2022-03-11 | 豪夫迈·罗氏有限公司 | 与gprc5d结合的抗体 |
-
2023
- 2023-01-09 JP JP2024541191A patent/JP2025504795A/ja active Pending
- 2023-01-09 TW TW112100924A patent/TW202334234A/zh unknown
- 2023-01-09 WO PCT/CN2023/071314 patent/WO2023131328A1/zh not_active Ceased
- 2023-01-09 US US18/728,022 patent/US20250092135A1/en active Pending
- 2023-01-09 CN CN202380016649.XA patent/CN118510810A/zh active Pending
- 2023-01-09 EP EP23737190.1A patent/EP4464722A4/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | The development of bispecific antibodies and their applications in tumor immune escape | |
| ES2801873T3 (es) | Anticuerpo de PDL-1, composición farmacéutica del mismo y sus usos | |
| Kontermann et al. | Bispecific antibodies | |
| AU2004242847B2 (en) | Pharmaceutical composition comprising a bispecific antibody for EpCAM | |
| JP2025504795A5 (https=) | ||
| JP2022516557A5 (https=) | ||
| Xiong et al. | Efficient inhibition of human B-cell lymphoma xenografts with an anti-CD20× anti-CD3 bispecific diabody | |
| TW201040265A (en) | Multispecific antibodies comprising full length antibodies and single chain Fab fragments | |
| Müller et al. | Bispecific Antibodies | |
| JP2023159379A (ja) | Ｐｄ－１とｖｅｇｆを標的とした四価二重特異性抗体、その製造方法および用途 | |
| WO2023051727A1 (zh) | 结合cd3的抗体及其用途 | |
| JP2025508066A (ja) | 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 | |
| CN106831996A (zh) | 新型双特异性抗体及其用途 | |
| CN113490690A (zh) | 异源二聚体融合蛋白 | |
| Acheampong | Bispecific antibody (bsAb) construct formats and their application in cancer therapy | |
| JP2022521305A (ja) | 抗ｐｄ－ｌ１抗体及びその使用 | |
| JP2025511288A (ja) | 抗ｐｖｒｉｇ抗体、その医薬組成物及びその使用 | |
| WO2018237341A1 (en) | A TARGET CELL-DEPENDENT T CELL ENGAGING AND ACTIVATION ASYMMETRIC HETERODIMERIC Fc-ScFv FUSION ANTIBODY FORMAT FOR CANCER THERAPY | |
| JP2024521701A (ja) | 抗ｃｄ１３７抗体及びその使用方法 | |
| CN113004416B (zh) | 靶向her2-cd137双特异性抗体的构建及其应用 | |
| Ko et al. | Engineering antibodies for dual specificity and enhanced potency | |
| CN120344558A (zh) | 双特异性/多特异性抗体及其用途 | |
| EP4682172A1 (en) | Anti-muc17, anti-cd3 and anti-cd28 trispecific antibody | |
| WO2025201240A1 (en) | Antibodies targeting cd3, cd28, and pd-l1 and uses thereof | |
| Vega et al. | New antibody formats |